Small sample sizes used in previous studies result in a lack of overlap between the reported gene signatures for prediction of chemotherapy response. Although morphologic features, especially tumor nuclear morphology, are important for cancer grading, little research has been reported on quantitatively correlating cellular morphology with chemotherapy response, especially in a large data set. In this study, we have used a large population of patients to identify molecular and morphologic signatures associated with chemotherapy response in serous ovarian carcinoma.A gene expression model that predicts response to chemotherapy is developed and validated using a large-scale data set consisting of 493 samples from The Cancer Genome Atlas (TCGA)...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by ...
Background: Small sample sizes used in previous studies result in a lack of overlap between the repo...
<div><h3>Background</h3><p>Small sample sizes used in previous studies result in a lack of overlap b...
Small sample sizes used in previous studies result in a lack of overlap between the reported gene si...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
AbstractArray comparative genomic hybridization (aCGH) and microarray expression profiling were used...
<p>(A) Identification of gene signature differentially expressed in chemoresistant and chemosensitiv...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
The majority of patients with high-grade serous ovarian cancer (HGSOC) initially respond to chemothe...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by ...
Background: Small sample sizes used in previous studies result in a lack of overlap between the repo...
<div><h3>Background</h3><p>Small sample sizes used in previous studies result in a lack of overlap b...
Small sample sizes used in previous studies result in a lack of overlap between the reported gene si...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
AbstractArray comparative genomic hybridization (aCGH) and microarray expression profiling were used...
<p>(A) Identification of gene signature differentially expressed in chemoresistant and chemosensitiv...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
We investigated whether prognostic information is reflected in the expression patterns of ovarian ca...
The majority of patients with high-grade serous ovarian cancer (HGSOC) initially respond to chemothe...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically divers...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Background Chemotherapy resistance remains a major obstacle in the treatment of women with ovarian c...
Standard treatment of patients with advanced stage ovarian cancer is surgical debulking followed by ...